O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

5th Tumor Models Boston July 2017 Brochure

Tumor Models Boston 2017 will address the preclinical & clinical developments of the most promising therapies including targeted therapies, check-point inhibitors & CAR-T therapies and how these findings can be utilized to bridge the gap between preclinical and clinical studies.

Livros relacionados

Gratuito durante 30 dias do Scribd

Ver tudo

Audiolivros relacionados

Gratuito durante 30 dias do Scribd

Ver tudo
  • Seja o primeiro a comentar

  • Seja a primeira pessoa a gostar disto

5th Tumor Models Boston July 2017 Brochure

  1. 1. July 18-20 2017, Boston, MA Researched & Developed By: Event Partners Including: Uncover the Latest Preclinical & Clinical Insights to Advance Your Oncology Pipeline Tel: +1 212 537 5898 | Email: info@tumor-models.com Tumor Models www.tumor-models.com 30+ Expert Speakers Including: Barbara Joyce-Shaikh Associate Principal Scientist, Immunoncology Merck Research Laboratories Hui Wang Principal Scientist, In Vivo Pharmacology, Oncology Research & Development Pfizer Andrew Rhim CPRIT Scholar in Cancer Research, Associate Director for Translational Research in Pancreatic Cancer Research MD Anderson Cancer Center David Teachey Associate Professor of Pediatrics, Divisions of Hematology and Oncology Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine • Optimize Model Selection & Characterization • Advance Your Preclinical Predictions into the Clinic • Discover Valuable Clinical Data to Drive Your Preclinical & Translational Studies This conference was amazing! The collaborations I created are priceless. Thanks so much! Past Attendee of the Tumor Models Series, Roswell Park Cancer Institute Book now to save up to $700
  2. 2. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models 11 33 22 44 55 Optimize your strategies for selection & characterization of in vivo preclinical models Key takeaways to implement: Top case studies to discover: Discover how Merck are advancing the use of humanized mice models in the development of cancer immunotherapies Explore preclinical model advancements in ex vivo assays, 3D models & organoid in vitro models Learn from Kite Pharma on how to utilize ex vivo assays for the development of T cell therapies Take clinical outcomes from targeted & IO therapies to advance preclinical development & translational decision making Uncover how Novartis are advancing in vitro 3D models to bridge the gap with animal models Evaluate your preclinical predictions for the development of combination therapies with targeted & immunotherapies Explore how University of Penn Medical School are harnessing clinical outcomes of CAR-T therapies to enhance translational insights from preclinical studies Advance the predictability of preclinical models through clinical insights from CAR-T & immune-checkpoint therapies Unlock how Genentech are developing and harnessing toxicology models for safety assessments of IO therapies This was a nice meeting with a good sized group of participants that made it easy to choose to both sit back and soak it all in or to meet one-on-one for in-depth discussions Past Attendee of Tumor Models Boston, Agilux Laboratories It was a well- structured meeting, with a good balance of speakers, social interaction and exhibitors. I felt I got a lot accomplished within a very short period of time. Most helpful for someone with a busy schedule Past Attendee of Tumor Models Boston, KK Womens and Childrens Hospitals Hear what previous attendees have to say: The only forum dedicated to advancing preclinical oncology for optimized translational & clinical success With the oncology industry rapidly transitioning from traditional targeted therapies to cancer immunotherapies, particularly in combination, the preclinical research now needs to harness the clinical findings to advance preclinical outcomes of future therapies. The 5th Annual Tumor Models Boston continues to showcase the latest advancements in the application of preclinical models to enhance the translation of cancer therapies from animal to patient. Learn how the industry have been selecting & characterizing in vitro models, ex vivo assays, syngeneic, PDX, humanized mice models to optimize their application in preclinical and translational decision making for targeted therapies, IO therapies and combination therapies. With the industry well aware of the models available, you will uncover the valuable clinical lessons that are helping to transform preclinical research to safeguard future therapies. Discover how you can utilize clinical insights to extract more value from preclinical models and accelerate more safe and effective drug candidates into the clinic with greater confidence. This year’s Tumor Models Boston will address the preclinical & clinical developments of the most promising targeted and IO therapies including check-point inhibitors, CAR-T therapies and how these findings can be utilized to bridge the gap between animal and patient studies. Now is the time to harness clinical data to dictate preclinical model development, biomarker discovery & validation and combination therapy advancement. Take vital lessons from the clinic to progress future cancer treatments into the clinic more effectively and faster. Discover the preclinical strategies that are driving translational & clinical outcomes Catch up with the latest preclinical & clinical data to fast track your compounds into the clinic with confidence
  3. 3. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models Dedicated Speaker Faculty Tom Brennan Vice President, Pharmacology & Bioanalytics FivePrime Therapeutics Edward Rosfjord Senior Principal Scientist Pfizer Jayant Thatte General Manager Crown Bioscience Parker Cassidy Chief Commercial Officer Mitra Biotech Renuka Iyer Section Chief GI Medical Oncology Roswell Park Cancer Institute Saad Kenderian Assistant Professor of Medicine & Oncology Mayo Clinic Rick Huntress Director of Business Development, Clinical & In Vivo Services The Jackson Laboratory Shruthi Naik, Research Associate, Department of Molecular Medicine Mayo Clinic JoshuaBreunig AssistantProfessor,BoardofGovernors RegenerativeMedicineInstitute, DepartmentofBiomedicalSciences Cedars-Sinai Medical Center Brian Van Ness Professor, Department of Genetics, Cell Biology & Development, College of Biological Sciences University of Minnesota Cancer Center Frederick Roberts Sales Manager Fujifilm VisualSonics Mohammad Rashidian Postdoctoralfellow,CancerResearch Institute,BostonChildrenHospital Harvard Medical School Andrew Rhim CPRITScholarinCancerResearch, AssociateDirectorforTranslational ResearchinPancreaticCancerResearch MD Anderson Cancer Center Michael Brehm Associate Professor, The Robert and Sandra Glass Term Chair in Diabetes University of Massachusetts Medical School Christopher Murriel Senior Scientist II OncoMed Pharmaceuticals Jason Fleming Professor Department of Surgical Oncology MD Anderson Cancer Center Neal Goodwin, VP, Corporate Research Development Champions Oncology David Largaespada American Cancer Society Research Professor, Department of Pediatrics, Masonic Cancer Center University of Minnesota Vinagolu Rajasekhar Senior Research Scientist Memorial Sloan Kettering Cancer Center Sidi Chen Assistant Professor, Genetics Yale University Shiva Kazerounian Senior Scientist Berg Pharma Ran Li Postdoctoral Scientist, Roger Kamm’s Lab, Department of Biological Engineering & Mechanical Engineering MIT Barbara Joyce-Shaikh Associate Principal Scientist, Immunoncology Merck Research Laboratories Serena Silver Senior Investigator, Group Leader, Oncology Novartis Institutes for Biomedical Research David Teachey Associate Professor of Pediatrics, Divisions of Hematology & Oncology Children’sHospitalofPhiladelphia, UniversityofPennsylvaniaSchoolof Medicine Hui Wang Principal Scientist, In Vivo Pharmacology, Oncology Research & Development Pfizer Gregor Adams Principal Scientist Kite Pharma Inc Robert Li Toxicologist, Pharmacology SubTeam Leader Safety Assessment Genentech Moony Tseng Research Scientist II, Cancer Cell Line Factory Project Lead Broad Institute Maryland Franklin Vice President, Scientific Development MI Bioresearch Jenni Bernoulli COO Pharmatest Services Mohit Sachdeva Senior Scientist Horizon Discovery Alison Allan AssociateProfessor,Departmentsof Anatomy&CellBiology&Oncology SchulichSchoolofMedicineandDentistry Western University Leigh Ellis AssistantProfessorofPathology,DepartmentofOncologic Pathology Dana-Farber Cancer Institute
  4. 4. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models The following questions will be answered: • What are the current limitations with PDX models when studying the tumor microenvironment? • What methodologies are being used to develop humanized mice models from PDX models? • How is the development of humanized mice from PDX models overcoming these limitations? • What technical challenges need overcoming to harness these models for therapeutic development? Characterization of PDX Models in the Context of Humanized Mice Date: Tuesday July 18, 2017 | Time: 8.30-11.30 Dr. Vinagolu K. Rajasekhar, a Senior Research Scientist at the Memorial Sloan-Kettering Cancer Center, has been developing humanized patient derived xenograft (PDX) models of metastatic cancers in the institutional collaboration with Dr. John Healey, the Chief of Orthopedics Service. Dr. Rajasekhar has also purified cancer stem cells (CSCs) from human prostate cancer PDXs, discovered a novel set of biomarkers for the tumor driving cells, and delineated a clinically relevant functional signaling pathway in prostate cancer (www.Genomeweb.com). This study unveils a new direction to live bio-bank patient CSC-derived xenograft (PDXCSC) models of human tumors, which form an excellent and replenishable resource for understanding patient personalized signaling cross-talks between the CSCs and their specific microenvironment as well as for therapeutic testing and co-clinical trials. Workshop leader Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center Workshop A The following questions will be addressed: • How is the industry using humanized mice models for cell therapy preclinical studies? • What are the limitations in the current models for developing ex vivo therapies? • What strategies are the industry developing to test CAR-T therapies in preclinical models? • What developments are required to advance in vivo models for the preclinical testing of ex vivo therapies? Characterizing Preclinical Models for Advancing Cell Therapies Date: Tuesday July 18, 2017 | Time: 12.00-15.00 Saad S. Kenderian, MD is a senior associate consultant in the Division of Hematology at the Mayo Clinic. He holds the academic rank of Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine. After completing a combined fellowship in hematology and medical oncology, he joined the Division of Hematology at Mayo, received the Mayo Scholar award and joined the Translational Research Program of the University of Pennsylvania as a Mayo Scholar, where he worked in T cell immunotherapy for over two years. Workshop leader Saad Kenderian, Assistant Professor of Medicine & Oncology, Mayo Clinic Workshop B Pre-Conference Workshop Day The topics selected for this meeting are excellent and I would like to see those topics at future meetings Past Attendee of the Tumor Models Series, Dicerna Pharmaceuticals
  5. 5. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models The conference was very informative. I especially enjoyed the pre-conference workshops. I learned a great deal about the pros and cons of the models used for immunotherapy Past Attendee of Tumor Models Series, Calvert Laboratories The following areas will be discussed: • What are the current methodologies to develop humanized mice models? • What are the limitations of humanized mice models in preclinical practice? • Case studies on the use of humanized mice models for IO preclinical studies • What future developments are required to utilize humanized mice routinely? Optimizing Humanized Mice Models for the Advancement of Cancer Immunotherapies Date: Tuesday July 18, 2017 | Time: 15.30-18.30 Dr. Brehm received his Ph.D. from the Department of Microbiology and Immunology at the Pennsylvania State University College of Medicine. He is currently an Assistant Professor in the Program in Molecular Medicine at the University of Massachusetts Medical School and a member of the UMass Diabetes Center of Excellence. Dr. Brehm’s research program is focused on understanding how human effector T cells are regulated, and his laboratory is actively using “humanized” mice to model human T cell responses. Barbara Joyce-Shaikh completed her B.S in with Molecular Biology at San Jose State University. She has more than 20 years of biotech industry experience specializing in translational systems of immune function and immunoncology. She is currently a Project Leader in the Discovery Immunoncology group at Merck Research Laboratories. Her current research utilizes humanized mouse systems and is focused on understanding how tumor stroma and immune cell interactions can be altered with novel immunomodulatory agents in different cancers. Workshop Co-Leader Michael Brehm, Associate Professor, The Robert and Sandra Glass Term Chair in Diabetes, University of Massachusetts Medical School Workshop Co-Leader Barbara Joyce-Shaikh, Associate Principal Scientist, Immunoncology, Merck Research Laboratories Workshop C
  6. 6. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models Conference Day One | Wednesday July 19, 2017 8.00 Registration & Coffee 9.00 Chair’s Opening Remarks Taking Learnings from the Clinic to Advance Preclinical Models & Translational Decision Making Jayant Thatte, General Manager, Crown Bioscience 9.10 Translational Utility of PDX Models in Humanized Mice • Analysis of SCLC PDX models in a n=1 HuTrial • Provide a potential solution for stem cell donor-to-donor variability seen in humanized mice Jason Fleming, Professor Department of Surgical Oncology, MD Anderson Cancer Center 9.40 Improving Translational Decision Making to Influence Clinical Trial Design & Determine Endpoints • Bridging the model to human gap through effective and predictive biomarker strategy • Improving characterization of preclinical models • Ensuring more robust and rigorous translational research that ultimately help shorten development timelines Rick Huntress, Director of Business Development, Clinical & In Vivo Services, The Jackson Laboratory 10.10 Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform • The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization • Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor efficacy against several PDX tumors 10.40 Morning Refreshments & Speed Networking Track A: Advancing the Characterization of Preclinical Models Track B: Optimizing Model Development for Immunotherapies In Vivo Model Advancements: Syngeneic Models Enhancing the Use of Humanized Mice Models in Preclinical Studies 11.40 Development and Application of GEMM and GEMM- derived Syngeneic Models in Immuno-Oncology Drug Discovery • Addressing the preclinical needs of GEMM and GEMM-derived syngeneic models for IO drug discovery • How to improve characterization of above models to help model selection • Providing examples of utilization of GEMM and GEMM-derived syngeneic models in IO drug discovery Hui Wang, Principal Scientist, In Vivo Pharmacology, Oncology Research Development, Pfizer 11.40 Addressing the Latest Advancements in the Development of Routine Humanized Mice for Immunotherapies • Discussing the latest developments in humanized mice modeling • Presenting data from studies utilizing humanized mice for IO therapeutic development Michael Brehm, Associate Professor, The Robert and Sandra Glass Term Chair in Diabetes, University of Massachusetts Medical School 12.10 Identification of Novel Immune Regulators of Tumor Growth Using High-Throughput Screening In Vivo • We have generated a comprehensive library of substantially all human extracellular proteins including secreted proteins and the extracellular domains of membrane-bound proteins in soluble form • A portion of this library called the immunome contains 700 proteins with structural features characteristic of immune- activators and checkpoints • The immunome library was screened in four syngeneic mouse tumor models in vivo using RIPPSSM (Rapid In vivo Protein Production System) • Several hits were identified and CD80-Fc was prioritized for therapeutic development based on relative efficacy and tumor immune cell profiles Tom Brennan, Vice President, Pharmacology Bioanalytics, FivePrime Therapeutics 12.10 Humanized Mouse Models for Drug Discovery Research • Utilization of human cancer cell lines to model different aspects of human cancers • Discussing the relevance of humanized mouse cell subset profiles and how they compared to ex vivo human tumors and syngeneic models • Leveraging humanized systems for clinical translation, combination therapies, and biomarker development Barbara Joyce-Shaikh, Associate Principal Scientist, Merck
  7. 7. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models In Vivo Model Advancements: PDX Models Harnessing Ex Vivo Assays for the Development of Cell Therapies 14.10 The Use of PDX Models to Support Oncology Drug Development • Standard-of-care treatment from the perspective of response rates in the clinic and response rates in PDX • Evaluating response of PDX to standard-of-care treatment to validate this hypothesis and to identify dosages and schedules that can be used to identify sensitive and resistant PDX models Edward Rosfjord, Senior Principal Scientist, Pfizer 14.10 Developing Ex Vivo Preclinical Models to Enhance Translation from In Vitro to In Vivo for Cell Therapies • What models are being utilized to predict efficacy of engineered T-cell therapies? • Addressing the limitations in current models and how the industry are optimizing preclinical strategies for CAR-T cell therapies Gregor Adams, Principal Scientist, Kite Pharma Inc 14.40 Highly Characterized Patient-Derived Xenograft Collections for Preclinical Studies • Use of highly characterized PDX models allow efficient preclinical drug screening • Ex vivo proliferation studies using PDX models mirrors in vivo studies Mohit Sachdeva, Senior Scientist, Horizon Discovery 14.40 Preclinical Modeling of Chimeric Antigen Receptor T Cell Therapy and Combination Immunotherapy • Discussing preclinical modeling in CAR-T cell therapy • Addressing how preclinical modeling can be used for the evaluation of CAR-T cell toxicities • Presenting strategies for the development of combination immunotherapy Saad Kenderian, Assistant Professor of Medicine Oncology, Mayo Clinic 15.10 Use of High Frequency Ultrasound Imaging to Quantify Drug Responses in Patient Derived Xenografts of Renal Cell Carcinoma • The assessment patient-specific drug resistance to anti- angiogenic agents using the promising application of thepatient-derived xenograft model • To quantify responses to anti-angiogenic therapy within a clinically relevant time window, providing actionable data to inform therapy selection Frederick Roberts, Sales Manager, Fujifilm VisualSonics This session will finish at 15.25 15.10 Exploring Tumor Microenvironment Using Immuno-PET as a Predictive Tool • The effectiveness of immunotherapies is a direct result of changes they evoke in the tumor microenvironment • Identifying reproducible patterns in responders and non- responders is key to explaining the failure or success of a therapy • Using immunoPET to explore dynamics of immune infiltrates in response to therapy Mohammad Rashidian, Postdoctoral fellow, Cancer Research Institute, Boston Children Hospital, Harvard Medical School 12.40 Preclinical Mouse Models of Cancer Via Transposon- Mediated Mutagenesis or Gene Transfer • The development of the Sleeping Beauty (SB) transposon for forward genetic screens in mice: Immunoproficient, autochthonous models of cancer with clinically relevant genetic and biologic features • SB screens for sarcoma and mammary cancer: Identification of drivers of specific tumor biology • Using transposon-mediated gene delivery and CRISPR/Cas9 to model cancer in living mice • Porcine models of cancer David Largaespada, American Cancer Society Research Professor, Department of Pediatrics, Masonic Cancer Center, University of Minnesota 12.40 Focal Radiation in Combination with Chemotherapy Immunotherapy • Uses of focal radiation in preclinical oncology models • Combining focal radiation with chemotherapy in a human triple negative breast cancer model • Focal radiation in combination with immuno-therapy in a syngeneic murine glioblastoma model Maryland Franklin, Vice President, Scientific Development, MI Bioresearch This session will finish at 12.55 13.10 Networking Lunch 15.40 Afternoon Refreshments Poster Session 16.10 Tumor Models Interactive Roundtable Session In this 1 hour session, you will have the opportunity to catch up on the latest advancements within the field and learn from your fellow colleagues in this interactive format. The topics that will be discussed are the following: Developing predictive humanized mice- What are the current limitations? What added benefits can organoid cultures bring to preclinical studies? Fundamental pre- clinical experimental design: Setting up for clinical success How can we use preclinical models optimize the predictability of novel combination therapies? 1 2 3 4 17.10 Chair’s Closing Remarks 17.15 Drinks Reception Hosted By Crown Bioscience
  8. 8. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models Conference Day Two | Thursday July 20, 2017 8.00 Networking Coffee 9.00 Chair’s Opening Remarks Clinical Findings Experimental Platforms to Identify Effective IO Combinations Neal Goodwin, VP, Corporate Research Development, Champions Oncology 9.10 Advanced PDX Tumor Biology Platforms for Drug Advancement • Harnessing large collections of PDX models for more resolute efficacy predictions and the discovery of new therapeutic targets, resistance mechanisms, and biomarker signatures of response • How robust systems of myeloid engraftment, including hematopoietic stem cells for immune- oncology modeling and AML engraftment for high throughput multi-patient in vivo screens, have now provided expanded PDX screening with a wider scope of therapeutic agents • Advancement of coupled-PDX trials, where clinical trials are combined with companion PDX studies to help guide follow-on trial design Andrew Rhim, CPRIT Scholar in Cancer Research, Associate Director for Translational Research in Pancreatic Cancer Research, MD Anderson Cancer Center 9.40 Evaluating Preclinical Predictions for the Development of Combinations with Targeted Therapies Immunotherapies • Describing models used and key considerations for experimental design • Model responses and predictability of combination efficacy Parker Cassidy, Chief Commercial Officer, Mitra Biotech 10.10 A Novel Phenotypic Platform for Predicting Tumor Immune Response • Showcasing a novel platform to study and characterize immune cell interactions in response to therapies • How can this platform advance preclinical predictions for IO therapies? 10.40 Morning Refreshments Track A: Advancing Translational Progression of Targeted Therapies Track B: Advancing Translational Progression of Immunotherapies 11.10 Reverse Translation: Evaluating the Predictability of Preclinical Models Through Correlation Analysis of Clinical Data for Targeted Therapies • Discussing early clinical data and analysis into the correlation of preclinical predictions from models with clinical data • Addressing how clinical insights are optimizing preclinical studies for future therapies or combination therapies Christopher Murriel, Senior Scientist II, OncoMed Pharmaceuticals 11.10 Highlighting Clinical Outcomes of CAR-T Therapies to Enhance Translational Insights from Preclinical Models • Harnessing valuable clinical insights to advance preclinical translation for future therapies • How have clinical learnings advanced preclinical studies to better present the patient population David Teachey, Associate Professor of Pediatrics, Divisions of Hematology Oncology, Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine 11.40 Modeling Development of a Gene Expression Signatures of Response Resistance to Proteasome Inhibitors • Demonstrate the use of cell line models to develop a gene expression signature that predicts response or resistance to proteasome inhibitors in myeloma • Demonstrate gene signatures can be validated in stratification of clinical trial outcomes. • Show how gene expression signatures of therapeutic response can be applied in single cells to identify tumor heterogeneity in patients • Show how computational approaches to identify predictive signatures can be used using national data bases Brian Van Ness, Professor, Department of Genetics, Cell Biology Development, College of Biological Sciences, University of Minnesota Cancer Center 11.40 BPM 31510, A Clinical Stage Candidate, Demonstrates Potent Anti-Tumor Effect by Modulating Metabolism of Immune Cells • By improving the metabolic activity of immune-cells we can improve the Immunotherapies. • BPM31510 is a metabolic modulator • BPM31510 demonstrates potent anti-tumor efficacy in syngenic models • BPM31510 modulates the level of tumor infiltrating cells in a dose-dependent manner Shiva Kazerounian, Senior Scientist, Berg Pharma
  9. 9. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models Addressing Preclinical Model Advancements: Optimizing In Vitro Models Clinical Learnings from Immunotherapies to Drive Preclinical Predictions 13.40 Advances in In Vitro Model Development for Oncology Drug Discovery • Utilizing 3D models to understand the tumor microenvironment and interactions with immune cells • Addressing preclinical strategies to enhance the translation between in vitro and in vivo preclinical studies Serena Silver, Senior Investigator, Group Leader, Oncology, Novartis Institutes for Biomedical Research 13.40 Harnessing Humanized Mice to Improve Preclinical Predictions for Immuno Therapy and Nano Technology Approaches to Treat Cancers • Acknowledging and understanding the limitations of humanized mouse models • What does the perfect humanized model look like for ex vivo applications? Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center 14.10 Accelerating Prediction of Tumor Vulnerabilities Using Next-Generation Cancer Models • It is now possible to generate cell models at scale for many tumor types; in-line genomics is required to iteratively improve methods • Understanding the cancer cell model genomic stability across passages is critical for profiling the small molecular and genetic screens • We aim to expand the knowledge of cancer dependency map by adding the next generation cancer models Moony Tseng, Research Scientist II, Cancer Cell Line Factory Project Lead, Broad Institute 14.10 Influence of Microenvironment in Primary Bone Tumor Breast Cancer Models • Hormonal influence in orthotopic breast cancer tumor model • Bone microenvironment and breast cancer tumor growth • Immuno-oncology: tumor, bone and immune system in humanized mice Jenni Bernoulli, COO, Pharmatest Services 14.25 ModelingTumorMicroenvironmentUsingMicrofluidicSystems • Utilizing microfluidic platforms to study cancer cell-immune cell Interaction • In vitro system to study the mechanobiology of immune cell in the tumor microenvironment • Developing microfluidic platforms for testing immunotherapy Ran Li, Postdoctoral Scientist, Roger Kamm’s Lab, Department of Biological Engineering Mechanical Engineering, MIT 14.40 Biological Advances to Help Navigate the Nonclinical Safety Assessment Strategy in Cancer Immunotherapy • Highlighting the unique challenges in preclinical safety assessment for the development of cancer immunotherapeutics which may not be optimally characterized using conventional toxicology models or strategy • Discussing the opportunities of modifying the conventional toxicology models or developing novel approaches to support clinically relevant hazard identification and risk assessment Robert Li, Toxicologist, Pharmacology SubTeam Leader Safety Assessment, Genentech 14.55 Circulating Tumor Cell (CTC) Analysis in Preclinical Models of Cancer Metastasis • Although a number of quantitative tools have been previously developed to study in vivo metastasis, the detection and quantification of rare metastatic events has remained challenging • To discuss the use of circulating tumor cell (CTC) analysis as an effective means of tracking and characterizing metastatic disease progression in preclinical mouse models of breast and prostate cancer. • In particular, the use of clinically-relevant CTC technologies such as the Parsortix platform (ANGLE plc) to enhance the translation of cancer biology and new cancer therapies from animal to patient Alison Allan, Associate Professor, Departments of Anatomy Cell Biology Oncology Schulich School of Medicine and Dentistry, Western University- In collaboration with Angle 12.10 Addressing the Woodchuck Model for Hepatitis B Related HCC • Using the woodchuck model in the preclinical development of therapies for Hepatitis B related HCC • Discussing the high translatability of the preclinical insights gained from the woodchuck model into the clinic Renuka Iyer, Section Chief GI Medical Oncology, Roswell Park Cancer Institute 12.10 Comparative Oncology to Inform Clinical Translation of Immunotherapies • Overview and attributes of the Comparative Oncology approach • Utility of Comparative Oncology to facilitate clinical translation of Oncolytic virus and other immunotherapies • Currently available tools and development of new tools in development to facilitate immunotherapy development (e.g. biomarkers, imaging, genomics) Shruthi Naik, Research Associate, Department of Molecular Medicine, Mayo Clinic 12.40 Networking lunch
  10. 10. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models 15.10 Afternoon Refreshments Next Generation Model Development: Harnessing CRISPR Precision Gene Editing Sidi Chen, Assistant Professor, Genetics, Yale University 15.40 CRISPR Genome Editing Mouse Models of Cancer • Harnessing CRISPR for the precise development of physiologically relevant preclinical in vivo models for target discovery • Developing knock out models that are personalized to individual tumor types Joshua Breunig, Assistant Professor, Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center 16.10 Combining CRISPR/Cas9 Gene Targeting Single-Copy Somatic Transgenesis for Preclinical Brain Tumor Research • Overview of novel genetic methodologies for rapid, autochthonous tumor modeling • Using patient mutations in mouse models to accurately model clinical tumor subtypes in a “personalized” manner • Examples of preclinical studies investigating strategies to impede tumor growth and development by immunotherapy, metabolic targeting, and therapeutic mimicry • Employing CRISPR/Cas9 to enable rapid genetic manipulation of patient tumor cells for investigating the mechanisms of tumorigenesis and subsequent recurrence Leigh Ellis, Assistant Professor of Pathology, Department of Oncologic Pathology, Dana-Farber Cancer Institute 16.40 Utilizing 3D Organoid Modeling and Gene Editing for Accelerated Discovery in Prostate Cancer • Generate and validate 3D organoid models of prostate cancer to predict in vivo therapeutic response • Employing gene editing technology to discover drivers of aggressive prostate cancer • Harnessing gene editing to discover drivers of drug resistance in prostate cancer 17.10 Chair’s Closing Remarks 17.15 Close of the 5th Annual Tumor Models Boston 2017 Part of the Tumor Models Series
  11. 11. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models Horizon Discovery Horizon Discovery combines long scientific heritage in translational research with GENESIS™, a precision gene editing platform incorporating rAAV, CRISPR and ZFN technologies. Horizon supplies genetically-defined cell lines, gene-editing tools and services, custom cell line generation, molecular reference standards, and contract research services to approaching 1,000 academic, clinical and biopharmaceutical organizations. www.horizondiscovery.com Programme Partner Crown Bioscience Crown Bioscience provides Translational Platforms focused on fast-tracking candidates to identify biomarkers and patient responders based on the pharmacological response of human surrogate models. Power your Drug Discovery using the world’s largest commercial collection of well-characterised PDX in passage (HuPrime) plus a curated, searchable database of patient, genotypic and phenotypic data as well as pharmacological response (HuBase). Identify potential biomarkers (HuSignature™) based on pharmacological response or use your biomarker signature to identify models available for screening to confirm patient responder and non-responder populations (HuTrials™). Fast forward your drug discovery programs today. Partners, Sponsors Exhibitors Lead Partner Champions Oncology Champions Oncology was founded by renowned specialists in the field of cancer diagnosis, treatment, and research. The Champions Oncology team is comprised of seasoned oncology professionals passionately dedicated to working to accelerate oncology drug development, improve treatment outcomes and extend lives. Our core platform, the Champions TumorGraft™ offers an enhanced xenograft mouse avatar model for growing and testing human tumours. Champions Personalized TumorGrafts™ empower patients and physicians using an in vivo xenograft mouse avatar based diagnostic model that has shown to be predictive of a patients’ clinical response to cancer treatments and anticancer therapies. www.championsoncology.com Expertise Partner Additional Event Partners The Jackson Laboratory The Jackson Laboratory is an independent, nonprofit biomedical research institution and a National Cancer Institute-designated Cancer Center. Founded in 1929, the Laboratory applies its eight decades of expertise in genetics to increase understanding of human disease, advancing treatments and cures for cancer, neurological and immune disorders, diabetes, aging and heart disease. It models and interprets genomic complexity, integrates basic research with clinical application, educates current and future scientists, and empowers the global biomedical community by providing critical data, tools and services. www.jax.org Expertise Partner Mitra Biotech Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development discovery.Our unique CANscript™ platform delivers powerful, individualized treatment response predictions —with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and enhance drug discovery. www.mitrabiotech.com Expertise Partner Become a Commercial Partner at Tumor Models Boston: Contact Diane McKenna Commercial Director, Tumor Models Tel: +1 212 537 5898 Email: info@tumor-models.com www.crownbio.com Envigo provides essential research services, models and products for biopharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations. Our business is founded on a dedication to customer service and the expertise and experience of our 3,800 people. With over 50 locations worldwide we are committed to helping customers realize the full potential of their research and products as we work together to build a healthier and safer world. Programme Partner
  12. 12. Tumor Models Boston July 18-20 2017, Boston, MA Tel: +1 212 537 5898 Email: info@tumor-models.com www.tumor-models.com Tumor Models Academics Register Pay before Friday May 26, 2017 Standard Conference + 3 workshops $1796 (Save $600) $2096 (Save $300) Conference + 2 workshops $1497 (Save $600) $1897 (Save $200) Conference + 1 workshop $1298 (Save $500) $1698 (Save $100) Conference Only $1199 (Save $300) $1499 Workshop Only $299 Pricing Venue Register www.tumor-models.com/ register Tel: +1 212 537 5898 Email: register@hansonwade.com Mail: Hanson Wade 4th Floor, 52 Grosvenor Gardens, London, SW1W 0AU • 10% discount – 3 delegates • 15% discount – 4 delegates • 20% discount – 5 or more delegates Please note that discounts are only valid when three or more delegates from one company book and pay at the same time and that discounts are not applicable to academic pricing. Group discounts cannot be used in conjunction with other discounts. Team Discounts* Top 3 Benefits of Attending 1 2 3 Optimize Your Preclinical Studies Advance Model Selection Characterization Discover Translational Insights from the Clinic Venue The Colonnade Hotel 120 Huntington Avenue, MA, 02116, USA www.colonnadehotel.com Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the four- teenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH TERMS CONDITIONS Code:7134 Excellent Tumor Models meeting that was very well attended. Great program, speakers and panelists, which made for productive discussions, networking and exchange of ideas Past Attendee of the Tumor Models Series, MedImmune Drug Developers (Pharma Biotech) Register Pay before Friday May 26, 2017 Standard Conference + 3 workshops $2696 (Save $700) $2996 (Save $400) Conference + 2 workshops $2397 (Save $600) $2697 (Save $300) Conference + 1 workshop $2098 (Save $500) $2398 (Save $200) Conference Only $1799 (Save $400) $2199 Workshop Only $399 Solution, Service Product Providers Register Pay before Friday May 26, 2017 Standard Conference + 3 workshops $3696 (Save $700) $3896 (Save $500) Conference + 2 workshops $3297 (Save $600) $3597 (Save $300) Conference + 1 workshop $2898 (Save $500) $3198 (Save $200) Conference Only $2499 (Save $400) $2899 Workshop Only $499

×